Paxlovid for a Patient on a DOAC

Primary Item (H2)Sub Item 1 (H3)Sub Item 2 (H4)
Sub Item 3 (H5)
Sub Item 4 (H6)

Published: May 11, 2022

Authors:Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group, University of Waterloo School of Pharmacy

View PDF

https://doi.org/10.47326/ocsat.2022.03.61.2.0

OUTDATED

This version is outdated. Please see https://doi.org/10.47326/ocsat.2022.03.61.2.0 for the latest version of the Paxlovid for a Patient on a DOAC.

Document Information & Citation

Citation: Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group, University of Waterloo School of Pharmacy. Paxlovid for a patient on a DOAC. Ontario COVID-19 Science Advisory Table. 2022;3(61). https://doi.org/10.47326/ocsat.2022.03.61.2.0

Author Affiliations: The affiliations of the members of the Ontario COVID-19 Science Advisory Table and the Drugs & Biologics Clinical Practice Guidelines Working Group can be found at https://covid19-sciencetable.ca/about.

Declarations of Interest: The declarations of interest of the members of the Ontario COVID-19 Science Advisory Table and the Drugs & Biologics Clinical Practice Guidelines Working Group can be found at https://covid19-sciencetable.ca/about.

Copyright: 2022 Ontario COVID-19 Science Advisory Table. This is an open access document distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.